Abstract #3071

In Vivo Effect of Gadolinium-Based Contrast Agent on PET Quantification for Breast Imaging

Timothy J Allen¹, Leah C Henze Bancroft², Manoj Kumar², Tyler Bradshaw², Roberta M Strigel^1,2,3, Alan McMillan^1,2, and Amy M Fowler^1,2,3

¹Medical Physics, University of Wisconsin-Madison, Madison, WI, United States, ²Radiology, University of Wisconsin-Madison, Madison, WI, United States, ³Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, United States

The effect of gadolinium-based contrast agents (GBCAs) on dynamic PET quantification was investigated. Simultaneous PET/MRI was performed in patients with biopsy confirmed invasive breast cancer. Subjects received an injection of a GBCA as part of standard clinical dynamic contrast enhanced breast MRI exam. SUV_mean and SUV_max were calculated for the biopsy-proven breast cancer, aorta, liver, and benign fibroglandular tissue prior to and following GBCA injection. No significant difference in SUV_mean or SUV_max was measured suggesting GBCAs are unlikely to affect PET quantification in combined breast PET/MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here